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Abstract
Keywords:
Lung cancer remains a major health challenge in the
world. It is the commonest cause of cancer mortality in
men, it has been suggested that genetic susceptibility
may contribute to the major risk factor, with increasing
prevalence of smoking. Lung cancer has reached
epidemic proportions in India. Recently indoor air
pollution and dietary factors have been implicated in the
causation of lung Cancer development. Accumulating
evidences have highlighted that several polymorphisms
involve the metabolic activation or detoxification of
carcinogens derived from cigarette smoke have been
found to be associated with lung cancer risk. Many
studies have focused on the relation between the
distribution of polymorphic variants of different forms of
the metabolic enzymes and lung cancer susceptibility,
Few of human biotransformating enzymes (Phase I
enzyme: Cytochrome p450 enzymes, and Phase II
e n z y m e s : G l u t a t h i o n e - s - t r a n s f e r a s e s , N -
acetyltransferases) have been implicated in the formation
and scavenging of ultimate reactive metabolites. These
enzyme families are known to catalyze detoxification of
electrophilic compounds including carcinogens. The
treatment and prevention of lung cancer are major unmet
needs that can probably be improved by a better
understanding of the molecular origins and evolution of
the disease. This review will focus on major recent
advances in the molecular study of the origins and biology
of lung cancer.
Lung Cancer, Cytochrome p-450,
Glutathione-s-transferase, N-acetyltransferases
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Introduction
Lung cancer is the most common malignancy worldwide
and has the highest mortality rate among all cancers. In
United State, approximately 1700,000 deaths per year
were corresponding to one sixth of all cancer morality,
every year 1.2 million new cases of lung cancer were
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found. It is typically diagnosed in the severe stage; the
five year survival rate is less than 15 %. Worldwide the
lung cancer has the highest incidence and mortality
rates among all malignancies , and the risk increases
with exposure over a lifetime .The development of lung
cancer is strongly associated with both active and
passive cigarette smoking and other carcinogenic
compounds (such as NNK,
found in tobacco smoke are also present in
ambient air and diet , Smoking is known to be the
primary cause . Cigarette smoke contained several
thousand chemicals, of which about 50 compounds are
known carcinogens including polycyclic aromatic
hydrocarbons, aromatic amines and N-nitroso
compounds, Some of these compounds are reactive
carcinogens, but most are procarcinogens, which need
to be activated by Phase I enzymes such as those
encoded by the cytochrome P450 supergene family
and converted into reactive carcinogens. All these
reactive carcinogens can bind to DNA and form DNA
adducts capable of inducing mutations and initiating
carcinogenesis. CYPs are a multigene super family of
mixed function monooxygenases . Although of much
less influence than tobacco use, consumption of diets
high in fruits and vegetables have been associated with
a lower risk of lung cancer in many studies , , in
nonsmokers as well as in smokers  . Phase II enzymes
such as glutathione S-transferase are responsible for
detoxification of activated forms PAH epoxides. GSTs
are constitutively found in a wide variety of tissues, with
different characteristic patterns of GST isozymes. .The
major isoforms, which involve the metabolic activation of
carcinogens derived from tobacco smoke or
detoxification of those activated carcinogens .
In this review, we collect and discuss the evidence
reported up to date on the relationship between lung
cancer and genetic polymorphism of genes most
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World wide status
There is great variation in the prevalence of lung cancer in
different geographical areas. Almost 70% of all the new
cases of lung cancer in the world occur in the developed
countries. USA and Europe have the highest incidence
(>50/ 10 population) followed by China, Ireland, Malta,
Spain, Australia and New Zealand (non - Maori
population) with a moderate incidence (35-50 /10
population) and low incidence (<35/ 10 population)
countries include Utah (USA), Latin America, most Asian
countries, lce-land, Norway and Sweden. Lung cancer
was initially considered to be sporadic in India but it
constitutes 14.4% of all cancers . Lung cancer deaths
may rise to three millions per year by the year 2010  .
There are various risk factors for lung cancer
including asbestos, radon, occupational and
genetic factors. However, the most significant factor is
smoking which accounts for 80% of the attributed risk for
men and 45% of the cases for women. The intensive
research on the etiology of carcinogenesis in lung tissue
have shown that around 60-70% of lung cancer cases
might be associated with the exposure to environmental
carcinogens, while 30-40% with dietary habits  .
Nicotine (Fig.1) is a natural
ingredient in tobacco leaves where it acts as a botanical
insecticide When tobacco smoke reaches the small
airways and alveoli of the lung, the nicotine is rapidly
absorbed in the huge surface area of the alveoli and small
airways and dissolution of nicotine in the fluid of the
human lung, facilitates transfer across membranes  ,
After absorption, nicotine enters the bloodstream .it is
about 69% ionized and 31% unionized , Than enzymes
involved in the nicotine metabolism and factors affecting
the inter-individual differences, such as the genetic
polymorphisms . Nicotine acts through nicotinic
receptors. Nicotinic acetylcholine receptors (nAChRs)
normal human bronchial epithelial cells (BEC) express
and that form channels modulating Ca2+ metabolism and













Risk Factor for Lung Cancer Development
Lung cancer remains a highly lethal disease. Mean
cumulative five-year survival rates range from 13% to
21% in developed countries and from 7% to 10% in
developing countries, with an estimated global mean of 11
%  ,  .
Smoking
The causal relationship between smoking and lung
cancer has been accepted since the 1950s, when case-
control studies revealed a relative risk of 10. In cohort
studies, it has been demonstrated that lung cancer
mortality increases in proportion to the level of smoking,
this factor being more significant than the tar and nicotine
content of the tobacco  .
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shown the presence of saturable nicotinic binding sites
and nAChRs in BEC  .Investigators are working to
identify factors these can predict individual
susceptibility Single region of study is the family of
enzymes responsible for carcinogen activation,
degradation, and subsequent DNA repair . These
enzymes conceal gene deletions and polymorphisms
which can affect enzyme activity. It has been
hypothesized that an individual's enzyme profile is
associated with lung cancer risk and the metabolic
pathways they regulate have the potential to become
targets for preventive agents. This profile could be used
to recommend individuals and could be used to decide
on high risk individuals for specific chemoprevention
agents.
Tobacco smoke contains more than 60 carcinogens and
between these, more than 20 carcinogens are strongly
associated with lung cancer development  . The most
tarnished of these compounds include the polycyclic
aromatic hydrocarbons and the tobacco-specific
nitrosamine 4-(methylnitrsosamino) - 1-(3-pyridyl)-1-
butanones, both of which lead to genetic mutations
through DNA adduct formation  . There are two groups
of enzymes that are involved in DNA adduct formation
such as CYP P450 enzymes, encoded by CYP family
genes and GSTs. The carcinogenes are metabolically
activated by P450 enzymes and are either secreted or






Table: I-Resposible Factor For The Development Of Lung Cancer
Tobacco Smoke as genetic susceptibility to Lung
Cancer










Passive Smoking May be Lung cancer
3. Minerals Asbestos etc Asbestos fibers in air
Damaging cells
May  Lung cancer
4 Radioactive gases Radon etc. Occurs Naturally in Soil and Rocks
Damage to the lungs
May  Lung cancer
5. Lung Disease Tuberculosis (TB), May be lung cancer






Increased risk of lung cancer
A person have lung cancer once is more likely
to develop a second lung cancer compared to
a person who has never had lung cancer.
Brothers, sisters and children of those who
have had lung cancer have a slightly higher
risk of lung cancer
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By contrast, GSTs detoxify the intermediates of
carcinogens thus protecting against adduct formation. In
most of cases, these adducts compound are repaired but
from time to time the damage is severe enough to cause
apoptosis. Chronic exposure to these compounds often
leads to mutations in critical genes such as or
which lead to the initiation or progression of the disease.
8-oxoguanine is a major oxidative lesion that causes G-
to-T transversion, possibly leading to mutations in critical
genes concerned during lung cancer pathogenesis. 8-
oxoguanine is repaired by 8-oxoguanine DNA N-
glycosylase 1 ( ) and thus polymorphisms in
with its reduced enzymatic activity is possibly associated
with increased risk for lung cancer.Although it is generally
accepted that tobacco smoke causes lung cancer, not
everyone who smokes develops lung cancer. Many
studies have been examined the relationship between
polymorphic variants of the genes involved in tobacco
smoke metabolism and DNA repair pathways, including
and family genes and and the risk for
lung cancer, but the results of these studies have been
inconclusive however, a case control study has shown
that low activity of correlates with an increased risk
of lung cancer and suggesting that person with low
activity could be good candidates for smoking-
cessation programs.
Benzo[ ]pyrene, a carc nogen found in cigarette smoke
is metabolically begun by the P450 family of hepatic
enzymes (mainly )       . These intermediate
metabolites are chemically active and they can bind to
DNA and effect gene dysfunction. , epoxide
hydrolase (EH) and -acetytransferase ( ) detoxify
these products. Polymorphisms and/or gene deletions
result in modified metabolic activity . Various Studies
have suggested that genetic alterations in each of these
enzyme families can have the small affects on an
individual's risk of developing lung cancer. Gene-diet
interaction would be also requiring careful investigation, it
suggested that low levels of vitamin E can increase the
associated risk . Interactions with dietary
enzyme factors such as folate and subsequent folate
metabolism have also been documented  .
Human cytochromes P450 ( ) is a monomeric heam
containing enzymes. It is a large multigene family with the
differing substrate specificity. It plays very important role
for the activation of phase 1 reaction  . They are confined
to smooth endoplasmic reticulum and mitochondrial
membrane with NADPH-P450 reductase provide as
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Presently there are at least 50 different genes encoding
in human genome  , 40% homology of the
nucleotide sequences was reported for indicating
the conservativeness of the enzyme regions masked in
the lipid bilayer membrane (N-terminal) as well as those
responsible for the binding of P450 reductase (C-
terminal) and heam ring. Four families of cytochromes
P450 involved in xenobiotic oxidative metabolism in
lung tissue cells were identified: , ,
and . Most of the data concerning the role of
genes polymorphisms in relation to lung cancer
susceptibility has been reported for cytochromes
belonging to the and families  .
There are three genes - , and
they all are belonging to the gene family
and encoding cytochromes and
respectively. and are included in this
and called aryl hydrocarbon (AH) gene battery which
undergoes expression in lung cells. It localized on
chromosome 15q and its expression is regulated by
cytoplasmic receptor for PAH (AHR; aryl hydrocarbon
receptor). PAH once entered into cell binds to AHR and
the activatedAHR-PAH complex is then transported into
nucleus. Where in the cooperation with specific nuclear
translocator, it was binds to the regulatory sequence in
the enhancer region of and other genes of the
AH battery called xenobiotic responsive elements  .
and isoforms are characterized by
high degree of homology in their nucleotide sequences
but their cell and tissue distribution varies. and
catalyzes in chemical reactions, substrates for
which are polycyclic aromatic hydrocarbons (PAH) and
dicyclic/heterocyclic aromatic amines respectively and
thus resulting in the activation of these procarcinogens
and formation of mutagenic and genotoxic
metabolites  . For The activation of genes results
in about 100-fold increase of the mRNA and enzyme
concentration in the cell . It was induced the
expression of for the expression of many
concerning regulatory proteins that causes difficulties in
the interpretation of the role of gene
polymorphism in determination of the individual
differentiation in PAH metabolism. Many of the single
nucleotides polymorphisms have been identified in
gene. It has localized on chromosome 15q22.
An MspI polymorphic site (also referred to as m1) at the
3_ non-coding region of the gene, characterized by the
T6235C transition, has been identified (
allele). Another polymorphism (m2), located in
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transition resulting in a synthesis of an enzyme with valine
rather than isoleucine at position 462 (
). Such amino acid exchange takes
place in a region involved in heam binding and it may be
associated with significant increase in enzyme activity
and thus production of reactive genotoxic metabolites .
Alleles and have been
associated with the increased activity of respective
enzyme isoforms. Some of studied shows
allele have increased levels of PAH-DNA
adducts and higher rate of mutations in person who
were smoked . In Japanese population,
and alleles was shown to cause a seven-fold
increase in the susceptibility to squamous cell carcinoma
(SqCC) of lung, especially in individuals less exposed to a
tobacco smoke also showed an increased rate of the
mutant allele in patients suffering from lung
cancer (21.2% in patients versus 10.6% in
controls).Similar results were obtained in Indian
population. The tobacco smoking dramatically increase
the risk for SqCC development in carriers of at least one
allele of or .
-acetyltransferases (NAT) are cytosolic enzymes
present in liver and other tissues in majority of mammals.
Only two isoforms of these enzymes were identified in
human cells: and . Both enzymes are closely
related although their substrate specificity is different.
However, there is no substrate acetylated solely by one
ore the other enzyme  . These enzymes were the non-
intron gene group and both were mapped to chromosome
8p ( : 8p23.1; : 8p22). A encoding for
none physiologically active protein has also been
detected (at locus 8p22). undergoes expression in
most of human tissues and expression takes place
predominantly in liver, intestine and to a lower extent in
lung  , these xenobiotics containing aromatic amine (R-
NH2) or hydrazine (R-NH-NH2) groups it was catalyzed
and transformed into aromatic amides (R-NH-COCH3)
and hydrazides (R-NH-NH COCH3). This reaction - the
acetylation is the major biotransformation pathway of
such compounds .
All-embracing research has revealed that these two
acetylation phenotypes have different proportions within
the human population depending on the geographical
region about 70% of people living in Egypt, Saudi Arabia
and Morocco were found to be slow acetylators, while in
black Africans the proportion varies widely from 20 to
80%. In Caucasians and Asians the proportion is around
50 and 25%, respectively. The lowest frequency of slow





































- and - mediated -acetylation of aromatic
amine leads to either reduction or enhancement of their
toxic potential. It might, on one side, result in production
of less toxic respective amides, but on the other side,
following the -mediated -hydroxylation might
result in production of highly genotoxic acetoxy esters
and further into nitrenium and carbonium ions easily
forming adducts with DNA     . An assortment of
mutations within the gene was identified. It was
acetylase the product. It was divided into two groups
one is fast acetylator and second is slow acetylator.
at least one allele is of wild type which had
performed fast acetylation and second have slow
acetylation phenotype is underlined by a lower stability
or activity of enzymatic product what is believed to be a
consequence of three common mutations within
. Contradictory data were
obtained analyzing the relationship among the
acetylator genotype and the risk of lung cancer.
Increased risk of lung cancer in homozygotic carriers of
allele (fast acetylators) was reported. Most of
the studied documenting no effect of gene
polymorphism on lung cancer risk in various groups,
can also be found . Nevertheless, authors seem to
confirm a modulatory effect of smoking status on -
associated lung cancer risk. While in non-smokers, the
slow acetylator phenotype determining genotypes
seem to be associated with increased risk of lung
cancer, among smokers; such genotypes are rather
protective .
The glutathione S-transferases (GSTs), forming a
superfamily. In human cells, six classes of cytosolic
isoforms - Alfa (GSTA), Mi (GSTM), Pi (GSTP), Theta
(GSTQ), Zeta (GSTZ), Sigma (GSTS), Kappa (GSTK)
and one microsomal isoform - GSTMic - can be found.
The classification is based simplifies the differences in
their primary structure. It catalyzes and detoxifies the
wide range of electrophilic substrates, play a significant
role in phase II biotransformation of xenobiotics. The
detoxification is achieved by the conjugation of
xenobiotics with glutathione, which eases the
neutralization of their electrophilic centre by it has -SH
group .
GSTs-coding enzymes are expressed in all occurring
cells of all tissues and organs, varies considerably.
Even though it is regulated by cell-specific
environmental, hormonal and genetic agents, and it is
also effected by age, sex, past and present diseases
and by various types of endogenous and exogenous
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was shown in gonads, colon and liver, providing the
maximum protection to germ line cells and cells
constantly exposed to harmful effects of carcinogenic
chemicals. Two allelic forms of , differing in amino
acid at position 172 but functionally identical, are
distinguishable: with lysine and with
asparagine at that position. A null genotype of
( ) associated with zero GSTM1 activity
common in white Caucasian population of Europe (40-





Polymorphism of Cytochrome p450, Glutathione-S-Transferase: *Shukla RK **Kant S ***Mittal B  *Bhattacharya S
GSTM1
GSTM1*0
DNA fragment in both copies  . Subjects with
genotype have been shown to be more
susceptible to lung cancer in several studies , our
latest study results also showed that same data  .
Taking care of lung cancer patients will remain a daily
task for decades. It will be important to find out the
different molecular diagnostic marker for the treatment




Conclusion and future Prospects
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Fig. (1) Nicotine diffusion on human and lung and
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